**Core tip:** The clinical significance of routinely used pre-treatment fasting blood glucose, insulin, HbA~1c~ and homeostasis model of risk assessment was investigated in a cohort of colorectal cancer (CRC) patients. Despite all four metabolic markers were elevated in non-diabetic CRC patients, only elevated HbA~1c~ levels were significantly associated with advanced CRC stage and disease progression, showing a negative prognostic value both in terms of progression-free (HR = 1.24) and overall (HR = 1.36) survival after adjustment for major confounders. These results suggest that glycemic metabolic markers, mainly HbA~1c~, should be carefully monitored in CRC patients as they could provide important risk stratification information.

INTRODUCTION
============

Type 2 diabetes (T2D) and colorectal cancer (CRC) are among the major causes of morbidity and mortality worldwide, and their increasing prevalence represents a significant public health burden\[[@B1]-[@B3]\]. Several epidemiological studies and meta-analyses of published trials suggested that there is a significant association between T2D and increased risk of CRC\[[@B4]-[@B6]\], which is further suggested by the findings that combined treatment of metformin and 5-fluorouracil had a better anticancer effect than 5-fluorouracil alone, possibly by reverting epithelial-mesenchymal transition phenotype in cancer cells\[[@B7]\].

Among the mechanisms advocated to explain this association, hyperinsulinemia may play a pivotal role, acting as a potent cell mitogen capable of promoting colon cancer growth\[[@B8]\], an hypothesis that is corroborated by indirect findings of a harmful effect of insulin use for CRC risk\[[@B9],[@B10]\]. Other proposed explanations for the increased risk include obesity-related insulin resistance (IR)\[[@B11]\] and cytokine production\[[@B12]\], which may directly influence CRC growth not only through promotion of angiogenesis\[[@B13],[@B14]\], but also by inducing host inflammatory response\[[@B13],[@B15]\] or decreasing natural killer (NK) lymphocyte cytotoxic activity and, thus, the immunological defense against cancer\[[@B16]\].

Independently of the pathogenetic mechanism(s) advocated for the relationship between T2D and CRC, elevated levels of fasting glucose, fasting insulin, glycated hemoglobin (HbA~1c~) and IR evaluated by homeostasis model of risk assessment (HOMA-IR) have all been associated with increased CRC risk\[[@B17]-[@B30]\], but the results were often conflicting, with some studies suggesting a superiority of HbA~1c~\[[@B20],[@B26]\] and others placing emphasis on fasting blood glucose, insulin or on the composite index HOMA-IR\[[@B31]\].

Furthermore, whilst most of the studies have focused on the association between T2D or metabolic markers of impaired glucose metabolism and CRC risk, little is known on the impact of a deregulation of the glucoseinsulin axis on CRC progression and survival. The few available data come from selected diabetic populations\[[@B32]\], or obese individuals\[[@B30]\], while additional indirect evidences can be derived, once again, from T2D patients with CRC treated with metformin, suggesting that it could moderately improve survival outcomes\[[@B33]-[@B37]\].

Based on the above, we sought to investigate the potential prognostic value of routinely used glycemic parameters in non-diabetic CRC patients. To this purpose, we first designed a case-control study aimed at evaluating the behavior of glucose metabolism indexes in a population of CRC patients, representative of a general practice cohort, compared with non-cancer controls matched for sex, obesity and T2D frequency and blood lipid profile, in order to minimize possible metabolic-related confounders. Thereafter, based on the hypothesis that an association between pre-treatment fasting blood glycemic indexes (blood glucose, insulin, HbA~1c~ and HOMA-IR) and CRC-related survival outcomes might exist independently of T2D, the prognostic value of routinely used glycemic parameters towards progression-free and overall survival was prospectively evaluated.

MATERIALS AND METHODS
=====================

Patients and sample collection
------------------------------

Starting from January 2007, the PTV Bio.Ca.Re. (Policlinico Tor Vergata Biospecimen Cancer Repository) and the Interinstitutional Multidisciplinary Biobank of the IRCCS San Raffaele Pisana (SR-BioBIM, Rome, Italy) are actively involved in the recruitment of ambulatory patients with primary or metastatic cancer, who are prospectively followed under the appropriate Institutional ethics approvals, as part of a Clinical Database and Biobank project. Among these, a cohort of 224 CRC patients was eligible for the study. Inclusion criteria for the CRC patients from whom serum samples were stored in our Biobanks were: age above 18 years, an Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤ 2 and adequate hematological, hepatic and renal functions. History of alcohol or drug abuse, concurrent infectious or inflammatory diseases were all considered as exclusion criteria for the current analysis.

CRC was staged according to the TNM classification. Surgery was performed in 104 patients with primary CRC and 8 with resectable synchronous metastasis. The remaining 112 patients had relapsing/metastatic disease and entered the study prior to the start of chemotherapy. Among the non-metastatic population, 21/224 (10%) and 83/224 (38%) patients received neoadjuvant and adjuvant therapies, respectively. First-line chemotherapy was instituted in all patients with metastatic disease. Anti-cancer regimens used were all 5-fluorouracil-based in combination either with irinotecan (*n =* 97) or with platinum compounds (*n =* 114). Bevacizumab or cetuximab were administered in 68 (57%) and 36 (30%) metastatic CRC patients, respectively. Supportive drugs included erythropoiesis-stimulating agents (*n =* 3, 1%), granulocyte colony stimulating factors (*n =* 7, 2%) or corticosteroids (*n =* 40, 12%). No patient was lost at follow-up. Clinical features of CRC patients are summarized in Table [1](#T1){ref-type="table"}.

###### 

Clinical characteristics of colorectal cancer patients - comparison between patients with or without impaired glucose tolerance or type 2 diabetes

                                           **IGT or T2D**            ***P* value**             
  ---------------------------------------- ------------------------- ------------------------- -----------
  Age (yr)                                                                                     
  mean ± SD (range)                        64 ± 10 (30-83)           66 ± 8 (54-80)            0.127
  Sex, *n* (%)                                                                                 
  Males                                    103 (60)                  30 (59)                   
  Females                                  70 (40)                   21 (41)                   0.927
  Body mass index                                                                              
  mean ± SD (range)                        25.4 ± 4.1 (17.2-38.4)    26.5 ± 4.2 (17.2-38.4)    0.105
  HOMA index                                                                                   
  Median (IQR)                             2.80 (1.83-4.79)          6.48 (3.95-10.26)         \< 0.0001
  HbA~1c~                                                                                      
  mean ± SD (range)                        5.72 ± 0.36 (4.30-7.10)   6.87 ± 1.25 (5.30-13.0)   \< 0.0001
  Blood lipids (mg/dL)                                                                         
  Total cholesterol                        187 ± 42                  189 ± 48                  0.782
  HDL cholesterol                          47 ± 12                   44 ± 13                   0.284
  LDL cholesterol                          113 ± 38                  117 ± 41                  0.618
  Triglycerides                            136 ± 69                  138 ± 52                  0.838
  Site, *n* (%)                                                                                
  Colon                                    126 (73)                  33 (65)                   
  Rectum                                   47 (27)                   18 (35)                   0.293
  Histological diagnosis, *n* (%)                                                              
  Adenocarcinoma                                                                               
  Mucinous                                 30 (17)                   10 (20)                   
  Non-mucinous                             140 (81)                  40 (78)                   
  Others[1](#T1FN1){ref-type="table-fn"}   3 (2)                     1 (2)                     0.933
  ECOG performance status, *n* (%)                                                             
  0                                        150 (91)                  40 (82)                   
  1                                        14 (8)                    9 (18)                    
  2                                        1 (1)                     0 (0)                     0.129
  Stage, *n* (%)                                                                               
  I                                        3 (2)                     1 (2)                     
  IIA                                      26 (15)                   6 (12)                    
  IIB                                      4 (2)                     1 (2)                     
  IIIA                                     3 (2)                     1 (2)                     
  IIIB                                     37 (21)                   8 (15)                    
  IIIC                                     9 (5)                     5 (10)                    
  Metastatic                               91 (53)                   29 (57)                   0.875

Including 3 non diabetic patients with undifferentiated, squamous and mixed neuroendocrine cancers (one each) and one type 2 diabetes (T2D) patient with undifferentiated cancer. CRC: Colorectal cancer; IGT: Impaired glucose tolerance.

As control group, 112 unrelated individuals (mean age 60 ± 13, ranging from 31 to 83 years), paired for T2D rate (22%), obesity (BMI: 25.7 ± 4.4; 18% obese, 33% overweight) and blood lipid parameters were recruited in a 2:1 ratio from otherwise healthy individuals enrolled in the SR-BioBIM.

The study was performed in accordance with the principles embodied in the Declaration of Helsinki. All patients gave written informed consent, previously approved by our Institutional Ethics Committees.

Blood sampling and assessment of glycemic indexes
-------------------------------------------------

Fasting serum samples were obtained from each recruited subject, aliquoted and stored at -80 °C in the facilities of the PTV Bio.Ca.Re. or the SR-BioBIM. Samples from CRC patients were obtained at baseline prior to chemotherapy.

Routine chemistry studies, including fasting blood glucose (Hexokinase/Glucose-6-phosphate dehydrogenase-based methodology; Abbott Laboratories, Abbott Park, IL, United States), were performed on fresh samples within one hour from blood withdrawal on an ARCHITECT c8000 System (Abbott Laboratories). Fasting insulin levels were analyzed on serum samples using a fully automated Lumipulse G 600 II chemiluminescent enzyme immunoassay analyzer (Fujirebio Inc. Tokyo, Japan) according to the manufacturer's instructions.

The HOMA index (a marker of insulin resistance) was retrospectively calculated for each participating subject from fasting blood glucose and insulin according to the formula: glucose (mg/dL) × insulin (μIU/mL)/405\[[@B38]\].

HbA~1c~ levels were immediately measured on EDTA anticoagulated whole blood by the Tosoh G7 Automated HPLC Analyzer - HbA~1c~ Variant Analysis Mode (Tosoh Bioscience, Rivoli, TO, Italy), certified by the NGSP (National Glycohemoglobin Standardization Program) and traceable to the Diabetes Control and Complications Trial.

All measurements were ascertained while blinded to the sample origin and to study endpoint.

Statistical analysis
--------------------

Sample size of the study was based on the agreement to inclusion criteria and willingness to provide informed consent rather than on sample size calculations. However, estimation was later performed and showed that, given the observed proportions for patients and control groups for HbA~1c~ values and using a type I error probability of 0.05, the recruited population yielded a statistical power greater than 95%.

Data are presented as percentages, mean ± SD, or median and interquartile range. Student's unpaired *t-*test and ANOVA test were used for normally distributed variables. Appropriate non-parametric tests (Mann-Whitney *U*-test and Kruskal-Wallis ANOVA and median test) were employed for all the other variables. The cut-off values were generated from continuous data by receiver operating characteristic (ROC) curve analyses performed by MedCalc Statistical Software version 13.1.2 (MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2014).

Progression free (PFS) and overall survival (OS) represented the study endpoints. PFS was calculated from the date of enrollment until relapse or progression of disease. OS was calculated from the date of enrollment until death from disease. If a patient had not progressed or died, PFS or OS were censored at the time of the last follow-up. Survival curves were calculated by the Kaplan-Meier method and the significance level was assessed according to the log-rank test using a computer software package (Statistica 8.0, StatSoft Inc., Tulsa, OK). Cox-proportional hazards analysis was performed by a free web-based application (<http://statpages.org/>) to evaluate the association between clinical-pathological variables and PFS. For administrative censoring, follow-up was ended the date of March 31^st^, 2016. All tests were two-tailed and only *P* values lower than 0.05 were regarded as statistically significant.

RESULTS
=======

Of 224 prospectively recruited CRC patients, 51 (23%) had an established diagnosis of IGT (*n =* 15) or T2D (*n =* 36). In addition, 86 (38%) and 27 (12%) of the patients were overweight or obese, respectively. Fasting blood glycemic indexes (blood glucose, insulin, HbA~1c~) and HOMA-IR were retrospectively reviewed in the overall population, demonstrating that fasting insulin (*P \<* 0.0001), HOMA-IR (*P \<* 0.0001) and HbA~1c~ (*P \<* 0.001), but not blood glucose levels were higher in CRC patients compared to non-cancer controls matched for IGT/T2D or obesity (Table [2](#T2){ref-type="table"}). Of interest, pre-treatment levels of all four metabolic markers, including blood glucose, were significantly higher in CRC patients compared with controls once diabetic or overweight/obese subjects were excluded from comparative analysis (Table [2](#T2){ref-type="table"}).

###### 

Glycemic parameters in colorectal cancer patients and non-cancer controls

                             **CRC**           **Controls**     ***P* value**
  -------------------------- ----------------- ---------------- ---------------
  Overall population         *n* = 224         *n* = 112        
  Fasting blood glucose      106 ± 35          101 ± 39         
  (mg/dL)                    (65-415)          (61-289)         0.219
  Fasting insulin (μIU/mL)   14.2 (8.7-23.3)   9.0 (6.0-12.2)   \< 0.0001
  HbA~1c~ (%)                5.98 ± 0.83       5.63 ± 1.10      
                             (4.30-13.0)       (3.90-9.70)      0.001
  HOMA index                 3.5 (2.0-6.1)     2.0 (1.3-3.3)    \< 0.0001
  Non-diabetic               *n* = 173         *n* = 87         
  Fasting blood glucose      100 ± 25          87 ± 12          
  (mg/dL)                    (65-254)          (61-123)         \< 0.0001
  Fasting insulin (μIU/mL)   12.5 (8.5-18.6)   7.6 (5.1-10.9)   \< 0.0001
  HbA~1c~ (%)                5.72 ± 0.36       5.14 ± 0.42      
                             (4.30-7.10)       (3.90-6.10)      \< 0.0001
  HOMA index                 2.8 (1.8 -4.8)    1.7 (1.0-2.5)    \< 0.0001
  Non-diabetic normoweight   *n* = 90          *n* = 51         
  Fasting blood glucose      97 ± 19           84 ± 16          
  (mg/dL)                    (65-175)          (61-112)         0.0001
  Fasting insulin (μIU/mL)   10.8 (8.1 17.5)   6.5 (4.3-10.0)   \< 0.0001
  HbA~1c~ (%)                5.69 ± 0.31       5.13 ± 0.40      
                             (4.70-6.60)       (4.00-6.10)      0.0005
  HOMA index                 2.5 (1.8-4.0)     1.4 (1.0-2.4)    \< 0.0001

Data are reported as mean ± SD (range) or median (interquartile range).

ROC curves were, thus, generated from continuous variables measured in non-diabetic individuals. As summarized in Table [3](#T3){ref-type="table"}, the areas under the curve for fasting blood glucose, insulin, HOMA-IR and HbA~1c~ were: 0.657, 0.728, 0.738 and 0.860, respectively. At the designated criterion values all three parameters were associated with an increased CRC risk, although HbA~1c~ yielded the best performance, being associated with a sensitivity and specificity \> 80% and a 4.5 positive likelihood ratio (+LR) of CRC risk (Table [3](#T3){ref-type="table"}).

###### 

Receiver operating characteristics and Bayesian analysis of glycemic parameters

                                              **Fasting blood glucose**   **Fasting insulin**   **HOMA-IR**          **HbA~1c~**
  ------------------------------------------- --------------------------- --------------------- -------------------- ------------------
  AUC (SE)                                    0.657 (0.04)                0.728 (0.03)          0.738 (0.03)         0.860 (0.03)
  95%CI                                       0.596-0.714                 0.670-0.781           0.680-0.791          0.812-0.900
  Criterion                                   97 mg/dL                    12.5 μIU/mL           1.7%                 5.4%
  Sensitivity                                 42%                         50%                   81%                  82%
  Specificity                                 85%                         84%                   55%                  82%
  +LR (CI)                                    2.79 (1.63-5.06)            3.09 (1.87-5.41)      1.81 (1.43-2.30)     4.46 (2.96-7.06)
  -LR (CI)                                    0.69 (0.61-0.81)            0.60 (0.52-0.72)      0\. 35 (0.24-0.50)   0.22 (0.17-0.30)
  *P* value[1](#T3FN1){ref-type="table-fn"}   0.0001                      0.0001                0.0001               0.0001

Two-tailed Fisher Exact test. AUC: Area under the curve; +LR: Positive likelihood ratio; -LR: Negative likelihood ratio.

Despite the discriminative power of glycemic indexes at ROC analysis, there were no significant associations between pre-treatment fasting blood glucose or insulin and clinical-pathologic variables. On the other hand, mean pre-treatment HbA~1c~ was higher in mucinous (5.9% ± 0.4%) compared with non-mucinous (5.7% ± 0.3%, *P =* 0.007) adenocarcinomas and showed a trend to increasing concentrations from early (5.6%) to both advanced (5.8%, *P =* 0.044) and metastatic (5.8%, *P =* 0.020) CRC stages in non-diabetic patients (Anova test: F = 3.9, *P =* 0.021) (Figure [1](#F1){ref-type="fig"}). Thus, multivariate regression analysis (including age, sex, obesity, HOMA-IR, ECOG-PS and tumor site, histology and stage) was performed to assess possible determinants of HbA~1c~ in non-diabetic CRC patients. The final model by forward stepping showed that HOMA-IR (regression coefficient = 0.200, SE = 0.074, *P =* 0.008), mucinous features (regression coefficient = 0.196, SE = 0.072, *P =* 0.007) and advanced stage (regression coefficient = 0.177, SE = 0.074, *P =* 0.018) were all independent predictors of increased HbA~1c~.

![Box-plot of HbA~1c~ value distribution in non-diabetic colorectal cancer patients (*n* = 173) according to stages of disease. Solid lines: Mean values; boxes: Standard error; whiskers: 95%CI; closed circles: Outliers (Anova test including outliers: F = 3.9, *P* = 0.021).](WJG-22-9984-g001){#F1}

Overall, the mean time of follow up was 24.8 mo. Among patients with primary non metastatic CRC, 81/104 (78%) remained clinically free of disease, while 23/104 (22%) had progressive disease. Among patients with metastatic CRC, 3/120 (3%) had stable disease, 28/120 (23%) had a complete/partial response during chemotherapy, while 89/120 (74%) had CRC progression. Pre-treatment HbA~1c~ levels, but not fasting glycemia or insulinemia, were higher in patients who had CRC progression (5.8%) compared with patients in whom the disease did not progress (5.6%, *P =* 0.05).

To further evaluate its prognostic value, pre-treatment HbA~1c~ levels were divided into quartiles according to value distribution (median and interquartile range) in the 224 CRC patients (Q1: ≤ 5.3%; Q2: \> 5.3% and ≤ 5.7%; Q3: \> 5.7% and ≤ 6.1%; Q4: \> 6.1%). Overall, IGT/T2D or obesity were not associated to either PFS or OS at multivariate Cox proportional hazards survival analyses (data not shown). On the other hand, univariate Cox proportional hazards survival analyses showed that elevated pre-treatment HbA~1c~ levels had a negative prognostic value in terms of PFS \[HR = 1.30 (95%CI: 1.09-1.54)\] or OS \[HR= 1.43 (95%CI: 1.16-1.76)\]. No association with survival outcomes was observed for fasting blood glucose, insulinemia or the composite index HOMA-IR. These results were largely unmodified after adjustment for obesity or other variables known to be associated with PFS or OS, including disease stage, ECOG-PS, and tumor site and histotype \[HRs for HbA~1c~ quartiles: PFS: 1.24 (95%CI: 1.01-1.53); OS: 1.36 (95%CI: 1.05-1.74)\] (Table [4](#T4){ref-type="table"}). Of interest, the negative prognostic value of HbA~1c~ in terms of OS was further confirmed in a subgroup analysis performed after exclusion of IGT/T2D patients (Table [4](#T4){ref-type="table"}).

###### 

Cox proportional hazards survival regression analysis of the predictive value of clinical-pathological variables and glycemic indexes on progression-free and overall survival of colorectal cancer patients

  **Variable**                                        **Progression-free survival**   **Overall survival**                      
  --------------------------------------------------- ------------------------------- ---------------------- ------------------ -------
  Overall population (*n* = 224)                                                                                                
  Sex                                                 0.96 (0.68-1.36)                0.809                  0.82 (0.54-1.23)   0.336
  Obesity[1](#T4FN1){ref-type="table-fn"}             0.95 (0.73-1.24)                0.701                  0.88 (0.63-1.22)   0.448
  Site                                                0.93 (0.62-1.41)                0.745                  0.81 (0.49-1.34)   0.412
  Histological diagnosis                              0.90 (0.58-1.39)                0.629                  0.88 (0.53-1.45)   0.604
  Stage of disease[2](#T4FN2){ref-type="table-fn"}    1.95 (1.11-3.42)                0.021                  1.17 (0.58-2.34)   0.662
  ECOG-PS                                             1.54 (0.96-2.47)                0.075                  1.84 (1.05-3.23)   0.035
  Type of treatment[3](#T4FN3){ref-type="table-fn"}   1.37 (0.71-2.62)                0.346                  1.94 (0.80-4.74)   0.145
  Fasting glucose[4](#T4FN4){ref-type="table-fn"}     0.99 (0.80-1.21)                0.892                  1.06 (0.83-1.34)   0.657
  Fasting insulin[5](#T4FN5){ref-type="table-fn"}     0.90 (0.58-1.38)                0.619                  1.01 (0.62-1.62)   0.981
  Fasting HbA~1c~[6](#T4FN6){ref-type="table-fn"}     1.24 (1.01-1.53)                0.040                  1.36 (1.05-1.74)   0.018
  Non-diabetic patients (*n* = 173)                                                                                             
  Sex                                                 1.05 (0.69-1.59)                0.824                  0.79 (0.48-1.31)   0.355
  Obesity[1](#T4FN1){ref-type="table-fn"}             1.11 (0.83-1.50)                0.482                  0.91 (0.62-1.34)   0.640
  Site                                                1.09 (0.67-1.76)                0.740                  0.98 (0.54-1.79)   0.952
  Histological diagnosis                              0.91 (0.55-1.52)                0.728                  0.88 (0.49-1.61)   0.687
  Stage of disease[2](#T4FN2){ref-type="table-fn"}    1.78 (0.93-3.40)                0.083                  0.87 (0.39-1.93)   0.735
  ECOG-PS                                             1.69 (0.98-2.92)                0.060                  1.98 (1.02-3.85)   0.044
  Type of treatment[3](#T4FN3){ref-type="table-fn"}   1.46 (0.69-3.08)                0.321                  2.93 (1.01-8.56)   0.050
  Fasting glucose[3](#T4FN3){ref-type="table-fn"}     0.94 (0.74-1.20)                0.625                  0.91 (0.62-1.22)   0.531
  Fasting insulin[5](#T4FN5){ref-type="table-fn"}     1.01 (0.60-1.68)                0.976                  0.91 (0.51-1.64)   0.755
  Fasting HbA~1c~[6](#T4FN6){ref-type="table-fn"}     1.25 (0.97-1.62)                0.092                  1.40 (1.03-1.92)   0.034

Coded as normoweight if body mass index (BMI) ≤ 25, overweight if BMI \> 25 and ≤ 30, obese if BMI \> 30;

Coded as primary/metastatic;

Coded as neoadjuvant/adjuvant/metastatic;

Q1: ≤ 87 mg/dL; Q2: \> 87 mg/dL and ≤ 97 mg/dL; Q3: \> 97 mg/dL and ≤ 117 mg/dL; Q4: \> 117 mg/dL;

Q1: ≤ 8.7 μIU/mL; Q2: \> 8.7 μIU/mL and ≤ 14 μIU/mL; Q3: \> 14 μIU/mL and ≤ 23 μIU/mL; Q4: \> 23 μIU/mL;

Q1: ≤ 5.3%; Q2: \> 5.3% and ≤ 5.7%; Q3: \> 5.7% and ≤ 6.1%; Q4: \> 6.1%. ECOG-PS: Eastern Cooperative Oncology Group performance status.

Figure [2A](#F2){ref-type="fig"} and C demonstrates the Kaplan-Meier PFS and OS curves for CRC patients stratified on the basis of pre-treatment HbA~1c~ levels. As shown, patients with HbA~1c~ in the highest quartile had a worse 5-year PFS and OS rate compared to patients with HbA~1c~ levels in the lower quartile. Similar results were confirmed in non-diabetic CRC (Figure [2B](#F2){ref-type="fig"} and 2D).

![Kaplan-Meier curves of progression-free survival (A, B) and overall survival (C, D) of colorectal cancer patients. Comparison between patients stratified on fasting HbA~1c~ quartiles. First quartile (Q1): ≤ 5.3%; second quartile (Q2): \> 5.3% and ≤ 5.7%; third quartile (Q3): \> 5.7% and ≤ 6.1%; fourth quartile (Q4): \> 6.1%. A, C: Overall population; B, D: Non-diabetic patients.](WJG-22-9984-g002){#F2}

DISCUSSION
==========

Although the presence of a causal link between T2D and CRC risk has been proposed since long time, the role of a deregulation of glucose metabolic axis in CRC prognosis is far less explored, and mostly relying on indirect findings on glucose lowering drugs in T2D patients with cancer\[[@B33]-[@B37]\]. Furthermore, earlier studies have mainly used a "single marker approach" that does not take into account the complex synergistic interactions among the various metabolic features.

In the present study, we demonstrate the presence of increased pre-treatment fasting insulin and HbA~1c~ levels in a population of CRC patients representative of a general practice cohort, as compared to control subjects matched for obesity and T2D frequency. Furthermore, we provide evidence of an elevation of glycemic metabolic markers in normoweight non-diabetic CRC compared with matched control subjects.

Contrary to what reported for other tumors\[[@B39],[@B40]\], however, neither hyperglycemia nor hyperinsulinemia - and thus HOMA-IR - were associated to CRC clinical-pathological features, whereas pre-treatment HbA~1c~ levels were associated with advanced disease stage, especially of the mucinous histotype, in non-diabetic CRC patients. Most importantly, elevated pre-treatment HbA~1c~ levels acted as a negative prognostic factors for OS (HR = 1.43), independently of other well established prognostic factors (*e.g*., stage or ECOG-PS). Indeed, patients with HbA~1c~ levels in the highest quartile (*i.e*., \> 6.1%) had an approximately three-fold increased risk of dying from disease (5-year survival rate 24%) compared to patients with HbA~1c~ levels in the lowest quartile (*i.e*., \< 5.3%; 5-year survival rate 85%).

These results are in agreement and extend previous reports in cancer patients with T2D, in whom HbA~1c~ levels were evaluated as a marker of glycemic control\[[@B41],[@B42]\]. In particular, Siddiqui et al\[[@B41]\] reported that poorly controlled T2D - defined as a HbA~1c~ level ≥ 7.5% - was independently associated with a more advanced CRC stage at time of diagnosis and poorer 5-year survival, thus suggesting that in CRC patients with T2D, poor glycemic control is associated with a clinically aggressive cancer phenotype. Furthermore, no differences were observed in stage at presentation and 5-year mortality from CRC between well-controlled T2D and non-diabetic controls, suggesting that meticulous glycemic control might lead to a reduction in CRC mortality\[[@B41]\]. These findings are only in apparent disagreement with data obtained in the present study. Indeed, Siddiqui et al\[[@B41]\] performed a comparative analysis between well-controlled T2D and non-diabetic CRC patients (both control groups in their study) without reporting the impact of increasing HbA~1c~ on survival in either group, thus its possible prognostic significance. Furthermore, in our study the negative prognostic value of HbA~1c~ on survival outcomes was assessed in a general practice cohort of CRC patients that included only a moderate rate (23%) of IGT/T2D patients. Accordingly, we did not categorized HbA~1c~ on currently accepted cut-off value for metabolic control, but on quartiles calculated on the basis of the value distribution in the overall population. Of interest, CRC patients in the highest HbA~1c~ quartile (\> 6.1%) had the poorest survival. However, the small number of T2D patients enrolled did not confer enough power to perform a separate subgroup analysis. On the other hand, Boursi et al\[[@B42]\] reported no association between HbA~1c~ levels within 6 mo prior to cancer diagnosis and overall survival for CRC. This study is barely comparable with the results obtained in ours, since it enrolled only T2D patients in whom HbA~1c~ was evaluated as a marker of glycemic control.

More recently, Hope et al\[[@B43]\] reported the results of a meta-analysis investigating the relationship between HbA~1c~ and cancer in people with or without T2D. Major finding was that the majority of studies that investigated HbA~1c~ levels in relation to CRC risk identified positive associations. In particular, CRC cases were found to have higher HbA~1c~ levels than control subjects; however, the possibility of reverse causality cannot be completely excluded due to many shortcomings in population selection (*e.g*., different ethnicity) and lack of correction for CRC-related confounding factors known to increase HbA~1c~ levels such as iron deficiency anemia\[[@B43]\]. Thus, data to support the role of HbA~1c~ either for the identification of people at risk of cancers or to provide some insight into the potential progression of the disease are still lacking.

On the other hand, and to best of our knowledge, this is the first report suggesting that HbA~1c~ may have a prognostic significance for PFS of non-diabetic CRC, in whom HbA~1c~ was capable of discriminating a subset of patients with a more favorable outcome, with a 3-year PFS rate of 56% in patients with HbA~1c~ levels in the lower quartile (\< 5.3%) compared with 21% of those in the upper quartile (\> 6.1%). These results are scarcely comparable with the currently available evidences, as there are no data on the prognostic value of HbA~1c~ in the PFS of non-diabetic CRC.

As reported above, HbA~1c~ is a common measure of glucose metabolism, as it reflects average glycemia over the previous three months\[[@B44]\]. Accordingly, an elevated HbA~1c~ indicates poor long-term glycemic control and, possibly, chronic hyperinsulinemia. The data here reported are in agreement with the current knowledge that glycemic control is important in determining CRC development and progression. Moreover, the finding of a prognostic role of HbA~1c~ in non diabetic CRC patients could be explained by the common knowledge that, at the time of T2D diagnosis, patients usually have had hyperglycemia for more than a decade\[[@B45]\]. Thus, it is conceivable to hypothesize that colorectal carcinogenesis may recognize, among its causative mechanisms, a deregulated glucose metabolism and that CRC might become manifest long before T2D diagnosis.

There are, of course, some limitations that need to be acknowledged. The most obvious resides in the relatively small sample size that might have weakened the statistical power. Another limitation resides in the fact that, as evidenced by Hope et al\[[@B43]\], data on iron deficiency anemia were missing also in our study. However, the fact that erythropoiesis stimulating agents were administered to three patients only, indicates a satisfactory hemoglobin asset in the overall population. On the other hand, the strength of our analysis was represented by the use of samples collected and processed using standard operating procedures in the context of two large Biobanks. In addition, tests were run by a single laboratory under ongoing quality control protocols, hence minimizing the difference in sample analyses.

Based on the above, we may conclude that pre-treatment HbA~1c~ levels might have a negative prognostic value in CRC patients and, as such, should be carefully monitored, as they could provide important information in risk stratification. These results, however, should be regarded with caution and additional studies are required to prospectively evaluate their clinical value. Future investigations specifically designed to address the role of HbA~1c~ in the management of CRC, independently of T2D, may provide the rationale for lifestyle or glucose targeting dietary/pharmacologic interventions as a means of improving CRC outcomes.
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